1. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents Author(s): Doshi, Jalpa A., authorLi, Pengxiang, authorHuo, Hairong, authorPettit, Amy R., authorArmstrong, Katrina A., author Publication: Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018 Subject(s): Antineoplastic Agents -- economicsAntineoplastic Agents -- therapeutic useDrug CostsFinancing, Personal -- statistics & numerical dataMedication Adherence -- statistics & numerical dataAdministration, OralAntineoplastic Agents -- administration & dosageHealth Services AccessibilityPrescription Drugs -- economicsSocioeconomic FactorsTime FactorsHumansUnited States
2. General principles for evaluating the abuse deterrence of generic solid oral opioid drug products Publication: Silver Spring, MD : Center for Drug Evaluation and Research, November 2017 Subject(s): Abuse-Deterrent Formulations -- standardsAnalgesics, Opioid -- administration & dosageDrugs, GenericInvestigational New Drug ApplicationAdministration, OralAdministration, InhalationClinical Trials as TopicDrug Evaluation, PreclinicalInjectionsResearch DesignHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
3. Identifying patient harm from direct oral anticoagulants Author(s): Valentine, David, authorGaunt, Michael J., authorGrissinger, Matthew, author Publication: [Harrisburg, Pa.] : Pennsylvania Patient Safety Authority, June 2018 Subject(s): Administration, OralAnticoagulants -- administration & dosageAnticoagulants -- adverse effectsMedication Errors -- statistics & numerical dataAdultAgedAged, 80 and overAntithrombins -- administration & dosageAntithrombins -- adverse effectsDabigatran -- administration & dosageDabigatran -- adverse effectsForecastingHemorrhage -- chemically inducedMedication Errors -- prevention & controlMedication Errors -- trendsMiddle AgedPatient SafetyRivaroxaban -- administration & dosageRivaroxaban -- adverse effectsHumansPennsylvaniaUnited States
4. Oral anticoagulants: a review of common errors and risk reduction strategies Author(s): Andreica, Ivyruth, authorGrissinger, Matthew, author Publication: [Harrisburg, Pa.] : Pennsylvania Patient Safety Authority, June 2015 Subject(s): Anticoagulants -- adverse effectsAnticoagulants -- therapeutic useMedication Errors -- prevention & controlMedication Therapy ManagementAdministration, OralAnticoagulants -- administration & dosageDrug MonitoringDrug Prescriptions -- standardsInservice TrainingInternational Normalized RatioRisk ManagementHumansPennsylvaniaUnited States
5. Oral medications inadvertently given via the intravenous route Author(s): Shah-Mohammadi, Ali-Reza, authorGaunt, Michael J., author Publication: [Harrisburg, Pa.] : Pennsylvania Patient Safety Authority, [2013] Subject(s): Medication Errors -- prevention & controlMedication Errors -- statistics & numerical dataAdministration, OralInfusions, IntravenousInjections, IntravenousPatient safetyPharmaceutical Preparations -- administration & dosageRisk ManagementSyringesHumansPennsylvaniaUnited States
6. Radiology contrast concerns: reports of extravasation and allergic reactions Author(s): Gardner, Lea Anne, authorScott, Kelly, authorMagee, Mary C., author Publication: [Harrisburg, Pa.] : Pennsylvania Patient Safety Authority, June 2017 Subject(s): Contrast Media -- adverse effectsDrug Hypersensitivity -- epidemiologyExtravasation of Diagnostic and Therapeutic Materials -- epidemiologyAdministration, OralAdultAge FactorsChildContrast Media -- administration & dosageDiagnostic Imaging -- adverse effectsInfantInfusions, IntravenousInjections, IntravenousIodine Compounds -- adverse effectsPatient safetyRisk FactorsHumansPennsylvaniaUnited States
7. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system Publication: Silver Spring, MD : Center for Drug Evaluation and Research, December 2017 Subject(s): Biological AvailabilityDrugs, Investigational -- pharmacokineticsInvestigational New Drug ApplicationTherapeutic EquivalencyAdministration, OralBiopharmaceutics -- classificationDrugs, Investigational -- administration & dosageExcipientsPermeabilityProdrugsSolubilityHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.